Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2021 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Feb 5, 2021
Slide 1: Investor Presentation Q3FY21
Investor Presentation Q3FY21 February 5, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q3FY21 and 9MFY21
Key Highlights of Q3FY21 and 9MFY21 Growth returning back in India business, International business maintaining its quarterly momentum • Revenue from Operations grew by 6.2% YoY during the quarter, accompanied by 200bps expansion in EBITDA margin to 22.8% compared to 20.8% in Q3FY20 • Profit After T
Slide 4: Key Financial Highlights – Q3FY21 (Consolidated)
Key Financial Highlights – Q3FY21 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 15,140 14,239 23,181 21,818 Q3FY20 Q3FY21 International sales 7,739 7,254 Q3FY20 Q3FY21 Q3FY20 Q3FY21
Slide 5: Key Financial Highlights – Q3FY21 (Consolidated)
Key Financial Highlights – Q3FY21 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 14,304 5,291 13,474 4,533 61.8% 61.7% 20.8% 22.8% Q3FY20 Q3FY21 Q3FY20 Q3FY21 PBT (before Minority Interest) PAT (after Minority Interest) 4,510 5,434 3,820 4,046 Q3FY20 Q3FY21
Slide 6: Key Financial Highlights – 9MFY21 (Consolidated)
Key Financial Highlights – 9MFY21 (Consolidated) Particulars (₹ mn) 9MFY21 9MFY20 YoY growth Revenue from Operations 66,728 62,954 6.0% Gross Profit 41,174 38,448 7.1% Gross Profit margin 61.7% 61.1% EBITDA 16,513 11,704 41.1% EBITDA margin 24.7% 18.6% PBT 15,839 10,245 54.6% PBT margin 23.7% 16.3%
Slide 7: India Business
India Business India Business: Q3FY21 Sales of ₹ 15,140 million (6.3% YoY growth) • India sales contributed 66.2% to total sales in Q3FY21 • Significant recovery witnessed in acute therapeutic areas of anti-infectives, gastro intestinal, pain / analgesics and vitamins / minerals / nutrients with the
Slide 8: Secondary Sales Performance
Secondary Sales Performance Company’s India business recovering from the lows of Q1FY21 Alkem’s YoY Alkem’s YoY Alkem’s YoY Therapy segment growth in Q1FY21 growth in Q2FY21 growth in Q3FY21 Anti-infectives -22.1% -12.2% -3.9% Gastro Intestinal -4.0% 6.0% 12.5% Pain / Analgesics -14.1% -5.4% 3.2% Vi
Slide 9: US Business
US Business US Business: Q3FY21 Sales of ₹ 6,156 million (5.5% YoY growth) • US sales contributed 26.9% to total sales in Q3FY21 • In 9MFY21, the Company received 16 approvals (including 4 tentative approval) • As on December 31, 2020, the Company has filed a total of 149 ANDAs (including 2 NDAs) wi
Slide 10: US Business
US Business EIR for all the six facilities inspected by the US FDA Facility Capability Last inspection Status post last inspection St. Louis (US) Formulation February 2020 EIR# received in May 2020 Baddi (India) Formulation February 2020 EIR# received in March 2020 Daman (India) Formulation August 2
Slide 11: Other International Business
Other International Business Other International Business: Q3FY21 Sales of ₹ 1,582 million (11.7% YoY growth) • Other International Market sales contributed 6.9% to total sales in Q3FY21 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Australia and C
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 31, 2020 Non-Institution, 20.53% Promoter & Promoter Group, Institution, 62.43% 17.04% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 13: Thank You
Thank You For further information or queries please contact Gagan Borana Investor Relations – Alkem Laboratories Ltd. Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com